Pharmaxis Buying Topigen Pharma
Pharmaxis Ltd. (ASX: PXS) has agreed to acquire Topigen Pharmaceuticals Inc., a Montreal-based developer of respiratory therapeutics. The all-stock deal includes 2.3 million of Pharmaxis shares up-front, plus up to 5 million shares via earn-out. At current market value, the total deal would be worth around A$23.44 million. Topigen raised around US$58 million from firms like Fonds de Solidarite des Travailleurs du Quebec, MMV Financial, BDC Venture Capital, CDP Capital, T2C2 Capital, Investissement Desjardins Desjardins Venture Capital and Coller Capital.
13 January 2010•2 mins read
